Vimarsana
Biggest News Aggregation in the World

John Katzenellenbogen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Katzenellenbogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Katzenellenbogen Today - Breaking & Trending Today

Cadenza Bio Raises $2.44M Series Seed Funding - Vimarsana News

Cadenza Bio Raises $2.44M Series Seed Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Researchers modulate the activity of potential therapeutic target for triple-negative breast cancer - Vimarsana News

Researchers modulate the activity of potential therapeutic target for triple-negative breast cancer

Less than 20% of diagnosed breast cancers are designated "triple-negative," lacking three types of receptors often found in other breast cancer types.

Pathway preferential estrogens may be a safer alternative to hormone replacement therapy, study shows - Vimarsana News

Pathway preferential estrogens may be a safer alternative to hormone replacement therapy, study shows

Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A high-fat diet further exacerbates the disease, which can progress to cirrhosis and liver failure.

Postmenopausal women may benefit from estrogen compound research - Vimarsana News

Postmenopausal women may benefit from estrogen compound research

URBANA, Ill. – Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A

Leerink Partners Remains a Hold on Radius Health (RDUS) - Vimarsana News

Leerink Partners Remains a Hold on Radius Health (RDUS)

Markets Leerink Partners analyst Geoff Porges maintained a Hold rating on Radius Health (RDUS – Research Report) on April 22. The company’s shares closed last Friday at $20.90. According to TipRanks.com, Porges is a 3-star analyst with an average return of 5.9% and a 49.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma. Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $29.00. Radius Health’s market cap is currently $980.1M and has a P/E ratio ...

Source: markets.co